Table 4.
NSAID permeation parameters from selected commercial formulations through Strat-M® membrane in optimized in vitro test conditions.
| Commercial Formulation (API) |
Drug Flux (Jss) (mg/cm2h) |
Determination Coefficient (R2) |
Permeability Coefficient (KP) (cm/h) |
Total Amount Permeated at 12 h (AQ12 h) (mg/cm2) |
|---|---|---|---|---|
| Dolgit® cream 5% (IBU) | 1.12 ± 0.09 | 0.9735 ± 0.0095 | (2.24± 0.18) × 10−2 | 2.45 ± 0.31 |
| Ketonal® gel 2.5% (KTP) | 0.72 ± 0.06 | 0.9767 ± 0.0093 | (2.88 ± 0.25) × 10−2 | 1.61 ± 0.18 |
| Naproxen EMO gel 10% (NPX) | 1.52 ± 0.36 | 0.9878 ± 0.0070 | (1.52 ± 0.36) × 10−2 | 3.63 ± 0.85 |
| Olfen® gel 1% (DNa) | 0.21 ± 0.10 | 0.9272 ± 0.0309 | (2.11 ± 0.98) × 10−2 | 0.45 ± 0.22 |
| Traumon® gel 10% (ETF) | 3.11 ± 0.19 | 0.9110 ± 0.0532 | (3.11 ± 0.19) × 10−2 | 6.75 ± 0.58 |
| Voltaren® Emulgel® 1.16% (DEA) | 0.93 ± 0.06 | 0.9887 ± 0.0053 | (9.32 ± 0.61) × 10−2 | 2.31 ± 0.91 |
| Voltaren® Max 2.32% (DEA) | 1.81 ± 0.15 | 0.9921 ± 0.0079 | (9.05 ± 0.75) × 10−2 | 4.12 ± 0.43 |
| Ketospray ® 10% (KTP) | 4.07 ± 0.28 | 0.9378 ± 0.0343 | (4.07 ± 0.28) × 10−2 | 11.53 ± 1.05 |
| Traumon® aerosol 10% (ETF) | 4.94 ± 0.80 | 0.9463 ± 0.0428 | (4.94 ± 0.80) × 10−2 | 11.26 ± 1.97 |